Therefore, the knockdown of CENP-N combined with radiotherapy enhances radiation damage by suppressing the AKT/mTOR signaling pathway, downregulating Cyclin D1, and sensitizing NPC cells to radiotherapy during the G2/M phase. The gene discussed is CCND1; the disease is nasopharyngeal carcinoma.